NexImmune Corp - NEXI Net earnings per share for the last four quarters

Official company branding of NexImmune Corp (NEXI)

The GURU.Markets system provides a chart of the rolling earnings per share YoY change, where -306.10 records a new level. NexImmune, Inc. (NEXI) dynamics rely on a flexible development culture for T-cell therapies. Monetization potential is created through partnerships with immunotherapy pharma behemoths. The stability of the business model is maintained by strict control over the transportation of specialized reagents via certified carriers.

NexImmune (NEXI) Earnings per share for the last twelve months: for the period 02/11/2024 - 02/20/2024

NEXI (NexImmune): analytical breakdowns and indicator data

Initial company analysis:NEXI, NexImmune Corp
Mass-produced product of neximmune.com

Year-over-year (YoY) EPS growth (TTM) measures the percentage change in net income per share over a rolling twelve-month period. This indicator allows for an assessment of cost management efficiency and business scaling rates. The trend of the rolling annual EPS YoY helps investors identify profitability deviations from industry averages. For NexImmune, Inc. (NEXI), such fluctuations reflect the financial pressure of development stages, while the diversification of the immunotherapy pipeline serves as a tool for profit stabilization.

Direct competitors

Earnings per share for the trailing year IBRX (ImmunityBio)|IMCR: Net earnings per share (EPS TTM)|JANX - Net earnings per share for the last four quarters|Earnings per share for the last twelve months arcusbio.com|Net earnings per share for the last 12 months zymeworks.com (ZYME)|Earnings per share for the last twelve months Tango Therapeutics Inc (TNGX)|Net earnings per share for the last 12 months Iovance IOVA|Immatics NV - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Xencor Inc. XNCR|CMPX - Earnings per share for the last twelve months|REPL (replimune.com) - Earnings per share for the last 12 months|Lyell Pharma (LYEL) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Innate Pharma, S.A. (IPHA)|Net earnings per share for the last 12 months PYXS|CGEN - Net earnings per share for the trailing year|Net earnings per share for the last 12 months IOBT (IO Biotech Corp)|Earnings per share for the last four quarters STRO|Net earnings per share (EPS TTM) INKT (MiNK Therapeutics)|Earnings per share for the trailing year HOWL|Immix - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months ALX Oncology Holdings Inc.|CUE: Net earnings per share (EPS TTM)|PDS Biotech - Earnings per share for the trailing year|SONN (Sonnet BioTherapeutics Holdings Inc.) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) MAIA Biotech|Earnings per share for the last twelve months Liminatus Pharma LLC (LIMN)|LVTX: Earnings per one share for the last 12 months|NextCure Inc - Net earnings per share for the last 12 months|Leap Therapeutics, Inc. (LPTX) - Net earnings per one share for the last twelve months|Intensity Therapeutics Inc - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters senseibio.com SNSE|TOVX: Net earnings per share (EPS TTM)|Gritstone bio Inc. - Earnings per share for the trailing year|Net earnings per share for the last 12 months KA|TSBX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) VCNX|HARP: Earnings per one share for the last 12 months